Christopher A. Klebanoff: Publications

Christopher A. Klebanoff: Publications


Gejman, R, Klatt, M, Chang, A, Jones, H, Oh, C, Chandran, S, Korontsvit, T, Zakahleva, V, Dao, T, Klebanoff, CA, Schienberg, D. Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunology Research, accepted manuscript in press 2020.

Chandran, S. and Klebanoff, C.A. T cell receptor-based adoptive cancer immunotherapy: emerging efficacy and pathways of resistance. Immunological Reviews, Jul; 290(1): 127-147 2019. *Cover article.

Scott, A.C., Dunbar, F., Zumbo, P., Chandran, S.S., Klebanoff, C.A., Trivedi, P., Shakiba, M., Menocal, L., Appleby, H., Camara, S.J., Zamarin, D., Walther, T., Snyder, A.C., Femia, M.R., Comen, E.A., Wen, H.Y., Hellmann, M.D., Lauer, L., Levy, O., Glickman, M., Kaye, J., Betel, D., Philip, M., Schietinger, A. Thymocyte selection-associated HMG box protein TOX is 1 required for survival of antigen-specific T cells in tumours. Nature, Jul;571(7764):270-274, 2019.

S.K. Vodnala, R. Eil, R.J. Kishton, M. Sukumar, T.N. Yamamoto, N-H Ha, P-H Lee, M.H. Shin, S J. Patel1, Z. Yu, D.C. Palmer, M. J. Kruhlak, X. Liu, J.W. Locasale, J. Huang, R. Roychoudhuri, T. Finkel, C.A. Klebanoff, N.P. Restifo. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science. Mar 29;363(6434), 2019. *Cover article, accompanying commentary.

Yamamoto, T.N, Ping-Hsien Lee, P-H, Vodnala, S.K., Devikala, G., Kishton, R.J., Yu, Z, Arash Eidizadeh, A., Eil, R.L., Fioravanti, J., Gattinoni, L., Kochenderfer, J.N., Fry, T.J., Aksoy, B.A., Hammerbacher, J.E., Cruz, A.C., Siegel, R.M., Restifo, N.P., Klebanoff, C.A. T Cells Engineered to Overcome Death Signaling within the Tumor Microenvironment Enhance Adoptive Cancer Immunotherapy. Journal of Clinical Investigation. Feb 25;129(4):1551-1565, 2019. *Accompanying commentary.

Cruz, A.C., Ramaswamy, M., Ouyang, C., Klebanoff, C.A. et al. Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction. Nature Commun., 7: 13895, 2016.

Klebanoff, C.A. and Restifo, N.P. Customizing functionality and payload delivery for receptor-engineered T cells. Cell, 167: 304-306, 2016.

Eil, R., Vodnala, S.K., Clever, D., Klebanoff, C.A., et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature, 537: 539-543, 2016.

Clever, D., Roychoudhuri, R., Constantinides, M.G., Askenase, M.H., Sukumar, M., Klebanoff, C.A., et al. T cell-intrinsic oxygen-sensing proteins establish the lung as an immunologically permissive metastatic niche. Cell, 166: 1117-1131, 2016.

Roychaudhuri, R., Eil, R.L., Clever, D., Klebanoff, C.A., et al. The transcription factor BACH2 promotes tumor immunosuppression. Journal of Clinical Investigation, 126: 599-604, 2016.

Klebanoff, C.A., Scott, C.D., Leonardi, A.J., Yamamoto, T., et al. Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy. Journal of Clinical Investigation, 126: 318-334, 2016.

Klebanoff, C.A., Rosenberg, S.A., Restifo, N.P. Prospects of gene-engineered T cell immunotherapy for solid cancers. Nature Medicine, 22: 26-36, 2016.

Klebanoff, C.A., Spencer, S., Torabi-Parizi, P., et al. Retinoic acid controls the homeostasis of pre-cDC derived splenic and intestinal dendritic cells. Journal of Experimental Medicine, 210: 1961-76, 2013.

Gattinoni L.*, Klebanoff C.A.*, Restifo N.P. Paths to stemness: building the ultimate anti-tumour T cell.  Nature Reviews Cancer, 12: 671-84, 2012. * = equal contribution.

Klebanoff C.A., et al.  Determinants of successful CD8+ T cell adoptive immunotherapy for large established tumors in mice. Clinical Cancer Research, 17: 5343-52, 2011.

Klebanoff C.A., Yu Z., Hwang L.N., Palmer D.C., Gattinoni L., Restifo N.P.  Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood, 114: 1776-83, 2009.

Klebanoff, C.A., Gattinoni, L., Torabi-Parizi, P., et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory CD8+ T cells.  Proceedings of the National Academy of Science, 102: 9571-76, 2005.

Klebanoff, C.A., Finkelstein S.E., Surman, D.R., Lichtman, M.K., Gattinoni, L., Grewal, N., Spiess, P.J., Antony, P.A., Palmer, D.C., Tagaya, Y., Rosenberg, S.A., Waldmann, T.A., Restifo, N.P.  IL-15 Enhances the In Vivo Anti-tumor Activity of CD8+ T Cells. Proceedings of the National Academy of Science; 101: 1969-74, 2004.